<DOC>
	<DOCNO>NCT00053807</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth tumor cell . Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining interferon alfa interleukin-2 fluorouracil may kill remain tumor cell follow surgery . It yet know whether combine interferon alfa interleukin-2 fluorouracil effective observation surgery kidney cancer . PURPOSE : Randomized phase III trial compare effectiveness combine interleukin-2 , interferon alfa , fluorouracil observation alone treat patient undergone surgery kidney cancer high risk relapse .</brief_summary>
	<brief_title>Interleukin-2 , Interferon Alfa , Fluorouracil Compared With Observation Treating Patients Who Have Undergone Surgery Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect adjuvant combination therapy comprise interleukin-2 , interferon alfa , fluorouracil vs observation disease-free survival overall survival patient renal cell carcinoma high risk relapse radical surgery . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive interleukin-2 subcutaneously ( SC ) day 3 , 4 , 5 week 1 4 day 1 , 3 , 5 week 2 3 . Patients also receive interferon alfa SC weekly week 1 4 3 time weekly week 2 , 3 , 5 , 6 , 7 , 8 . Patients receive fluorouracil IV day 1 week 5 , 6 , 7 , 8 . - Arm II ( control arm ) : Patients receive adjuvant treatment disease progression . Quality life assess baseline 2 6 month randomization . Patients follow monthly 3 month ( arm I ) , every 3 month 1 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 550 patient ( 275 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary renal cell carcinoma meet 1 follow criterion : Stage T3b , T3c , T4 tumor Any pT stage nodal status pN 1 2 Any pT stage microscopic positive margin Presence microscopic vascular invasion Underwent surgical resection primary tumor within past month Removal clinical N+ disease require No evidence metastatic disease No evidence macroscopic residual disease PATIENT CHARACTERISTICS : Age 75 Performance status WHO 01 Life expectancy Not specify Hematopoietic WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Liver function test great 1.25 time upper limit normal ( ULN ) Renal Creatinine less 1.5 time ULN Cardiovascular No myocardial infarction within past 6 month No unstable angina pectoris Other Not pregnant nursing No prior concurrent malignancy would preclude study therapy comparisons No concurrent illness would preclude study therapy No concurrent active infection require antibiotic therapy PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy Endocrine therapy No concurrent corticosteroids No concurrent hormonal therapy Radiotherapy No prior radiotherapy Surgery See Disease Characteristics No prior major organ allograft Other No concurrent investigational drug , agent , device</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>